Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On March 30, 2020, Kennedy and Janssen applied to the Supreme Court of Canada for leave to appeal a Federal Court of Appeal decision relating to Kennedy's patent covering uses of REMICADE...
UPDATE: On January 8, 2021, the Supreme Court
of Canada dismissed Janssen's application for leave to appeal
(Docket No. 39099) (see article
here).
On March 30, 2020, Kennedy and Janssen applied to the Supreme
Court of Canada for leave to appeal a Federal Court of Appeal
decision relating to Kennedy's patent covering uses of
REMICADE (infliximab) and
Hospira's biosimilar, INFLECTRA: SCC Docket No. 39099. As
previously reported, the Federal Court of Appeal overturned
certain findings of infringement (relating to certain dependent
claims and separately, Celltrion) and remanded the issues of
obviousness and anticipation to the trial judge for
reconsideration: Hospira Healthcare Corporation v Kennedy Trust
for Rheumatology Research, 2020 FCA 30.
Originally published 30 April, 2020
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
